Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos


@ASCO poster walks #GU23 @PGrivasMDPhD @DrTylerStewart @alantanmd what a way to spend a Friday evening 🤗 https://t.co/pveKSvMSJv

  • 123456 Profile photo of Madelyn

    Excited to present data from TROPHY-U01, cohort 3 (phase 2 trial): SG + pembro looks very promising in advanced platinum-refractory urothelial Ca & met the primary endpoint: ORR 41%, CR 20%, 72% reduction in tumor size, mDOR 11 mo, median time to response 1.4 mo, median PFS 5.3 mo, median OS 12.7 months; toxicity as expected with either agent alone (neutropenia & diarrhea need close attention): role of a phase 3 trial?